Pulmonary surfactant, which is a complicated combination of phospholipids and proteins, makes it possible for alveolar gas and liquids to come into touch with each other at the surface of alveolar cells. This drops the surface tension and keeps the lung capacity when you breathe out. For breathing to work after birth, the surface tension between air and fluids must go down. Without lung surfactant, babies can't breathe. This is known as Infantile respiratory distress syndrome (IRDS). Lung surfactant is made, released, reused, and broken down by processes that are unique and tightly managed. In adult respiratory distress syndrome (ARDS), a major cause of illness and death after an infection, shock, or trauma, lung surfactant is lost or doesn't work. Mutations in surfactant balance genes like SFTPA, SFTPB, SFTPC, ABCA3, TITF1, and CSF2RA can cause lung diseases in babies, children, and adults. The disease can cause either long-term or short-term lung sickness. Without GM-CSF, alveolar macrophages can't break down surfactant lipids and proteins. It causes PAP, which stands for lung alveolar proteinosis. Increasing preference for animal-derived surfactant in the treatment of respiratory distress syndrome is expected to drive growth of the pulmonary surfactant market during the forecast period. The North American market holds the largest proportion of the global pulmonary surfactant market due to the rising incidence of respiratory infections. However, increasing number of adverse effects associated with pulmonary surfactant drugs restrain growth of the market for pulmonary surfactants.
The size of the global Pulmonary Surfactant Market is anticipated to expand at a CAGR of 4.50 percent over the period from 2022 to 2030.
Prominent Companies in the Pulmonary Surfactant Industry:
1. Boehinger Ingelheim
Boehinger Ingelheim is one of the world's largest pharmaceutical companies, was founded in 1885 and headquartered in Ingelheim, Germany. It has its sales offices in 17 countries. It serves more than 130 markets across its three business segments. In November 2022, Boehringer Ingelheim welcomed the new 2023 GOLD report that positions LAMA/LABA as the treatment of choice for the majority of COPD patients.
2. AbbVie Inc
AbbVie Inc is a pharmaceutical company, founded in 2012 and headquartered in North Chicago, Illinois. It operates in more than 70 countries. In May 2020, AbbVie Completes Transformative Acquisition of Allergan.
3. Chiesi Farmaceutici
Chiesi Farmaceutici is an Italian family controlled global pharmaceutical company, was founded in 1935 and headquartered in Parma, Italy. It operates in 31 countries. In April 2023, the partnership with Allinaire Therapeutics continues to work on the monoclonal antibody program as a possible treatment for pulmonary arterial hypertension. A collaboration has also begun with Aptar Digital Health to create a digital platform for managing respiratory diseases like asthma and COPD. Also, the strategic relationship with Kaia Health, a top digital therapy company, continues for the marketing of the Kaia COPD app for pulmonary rehabilitation in Europe. Kaia COPD is a digital health app that is listed in the German DiGA directory.
4. ONY Biotech Inc.
ONY Biotech Inc. is a pharmaceutical company specializing in the treatment of premature neonates that is a leader in the development of essential products, was founded in 1985 and headquartered in United States. It operates in the United States and around the world. In November 2020, ONY Biotech unveiled the results of a clinical trial on its aerosolized surfactant for infants with respiratory distress syndrome (RDS), a disorder that can result in collapsed lungs due to a lack of surfactant. Dr. Egan, one of the five scientists who founded ONY Biotech with the intention of creating a lung surfactant to treat premature infants born with respiratory distress syndrome (RDS), announced his retirement in October 2022.
5. Lyomark Pharma
Lyomark Pharma has become one of the most prestigious and well-known suppliers of sterile pharmaceuticals, was founded in 1989 and headquartered in Germany. Lyomark Pharma offers distribution licenses to international distribution partners and provides its own products directly to the German hospital market.
6. Abbott
Abbott is an American multinational medical devices and health care company, founded in 1888 with headquarters in Abbott Park, Illinois, United States. It operates in more than 160 countries. In December 2022, Abbott announced the launch of its latest-generation transcatheter aortic valve implantation (TAVI) system, NavitorTM, making the minimally invasive device accessible to individuals in India with severe aortic stenosis and high or extreme surgical risk.
7. Aviva Systems Biology Corporation
Aviva Systems Biology Corporation provides polyclonal and monoclonal antibodies for research need, founded in 2002 and headquartered in California, United States. It operates in more than 160 countries.
8. Windtree Therapeutics Inc.
Windtree Therapeutics Inc. is an American company, developing drug products (Pulmonary medicine) for patients with respiratory disease, founded in 1992 and is headquartered in Pennsylvania, United States. It operates in Taiwan, Milan, Taipei and Italy. In October 202, it said that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of new patent claims for isaroxime administration. The USPTO sends out a notice of allowance to show that the entry has passed the examination process. When the USPTO gives out the patent, which will happen soon, it will protect the intellectual property of isaroxime until late 2039.
9. Biomatik
Biomatik provides bioreagents for all applications, including ELISA Kits, recombinant proteins, custom gene synthesis, peptide synthesis, protein production, and antibody production, founded in 2002 and headquartered in Ontario, Canada. It is a globally operating diagnostics company represented in over 70 countries.
*Definition: Typically, pulmonary surfactant is a surface–active lipoprotein compound produced by type II alveolar cells. Both hydrophilic and hydrophobic regions contain proteins and lipids that make up the surfactant. Pulmonary surfactant is always essential because it lines alveoli to reduce physical phenomena, thereby averting atelectasis during respiration.
